Neet Pharmaceuticals

neetpharmaceuticals.com

Established in the year 2008, Neet Pharmaceuticals is known around the world for its wide array of Pharmaceutical Drugs. The broad line of products, best quality and appreciation from the consumers make us one of the to leading manufacturers and exporters in the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights, PHARMA TECH

SPECIALTY PHARMA EXPERT ADOPTS NAME OF GLOBAL PARENT TO REFLECT BREADTH OF OFFER THAT BRINGS A RARE AND SPECIAL PERSPECTIVE TO THE MARKET

Businesswire | April 26, 2023

news image

Global healthcare and business consulting services provider, Terebellum, has chosen to adopt the name of its global parent, AscellaHealth, to reflect the scale of its operations and breadth of expertise. The business specialises in providing end-to-end solutions to pharmaceutical manufacturers and other industry stakeholders to streamline product commercialisation, improve medication access, reduce costs and enhance patient outcomes for specialty and rare disease patients. ...

Read More

MAYNE PHARMA ANNOUNCES FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR E4/DRSP IN THE US

Mayne Pharma, Mithra | June 24, 2020

news image

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021. Developed by Mithra Pharmaceuticals SA (Mithra), E4/DRSP is a novel combined oral contraceptive pill containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally occurring estrogen that is...

Read More

Pharma Tech

IXENSOR RECEIVES STRATEGIC INVESTMENT FROM ROHTO PHARMACEUTICAL WITH A SEPARATE TECHNOLOGY LICENSING AGREEMENT

iXensor | April 28, 2022

news image

iXensor, the pioneer of mobile health, announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business. Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech&r...

Read More

Business Insights

AVIDIEN TECHNOLOGIES RECEIVES $4M INVESTMENT FROM BROADOAK CAPITAL PARTNERS

Avidien Technologies | February 02, 2022

news image

Avidien announced a new financing round of $4M from BroadOak Capital Partners. The investment will help Avidien expand its product roadmap, scale commercial production, and better serve research and pharmaceutical clients. "The partnership with BroadOak is exciting and ushers in the next phase for Avidien by creating the opportunity to quickly scale up the business with investments in new products, sales, marketing, and manufacturing." ...

Read More
news image

Business Insights, PHARMA TECH

SPECIALTY PHARMA EXPERT ADOPTS NAME OF GLOBAL PARENT TO REFLECT BREADTH OF OFFER THAT BRINGS A RARE AND SPECIAL PERSPECTIVE TO THE MARKET

Businesswire | April 26, 2023

Global healthcare and business consulting services provider, Terebellum, has chosen to adopt the name of its global parent, AscellaHealth, to reflect the scale of its operations and breadth of expertise. The business specialises in providing end-to-end solutions to pharmaceutical manufacturers and other industry stakeholders to streamline product commercialisation, improve medication access, reduce costs and enhance patient outcomes for specialty and rare disease patients. ...

Read More
news image

MAYNE PHARMA ANNOUNCES FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR E4/DRSP IN THE US

Mayne Pharma, Mithra | June 24, 2020

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021. Developed by Mithra Pharmaceuticals SA (Mithra), E4/DRSP is a novel combined oral contraceptive pill containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally occurring estrogen that is...

Read More
news image

Pharma Tech

IXENSOR RECEIVES STRATEGIC INVESTMENT FROM ROHTO PHARMACEUTICAL WITH A SEPARATE TECHNOLOGY LICENSING AGREEMENT

iXensor | April 28, 2022

iXensor, the pioneer of mobile health, announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business. Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech&r...

Read More
news image

Business Insights

AVIDIEN TECHNOLOGIES RECEIVES $4M INVESTMENT FROM BROADOAK CAPITAL PARTNERS

Avidien Technologies | February 02, 2022

Avidien announced a new financing round of $4M from BroadOak Capital Partners. The investment will help Avidien expand its product roadmap, scale commercial production, and better serve research and pharmaceutical clients. "The partnership with BroadOak is exciting and ushers in the next phase for Avidien by creating the opportunity to quickly scale up the business with investments in new products, sales, marketing, and manufacturing." ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us